Journal of peptide science: an official publication of the European Peptide Society, 27 (9), e3337
The inhibitory effect of GLP-1 on glucagon secretion in vivo was observed only when the blood glucose level was equal to or higher than the fasting level, at higher blood glucose levels, the inhibition of glucagon gradually increased (Holst, 2007), and when the blood glucose concentration was less than 3.7 m mol/L, GLP-1 lost its effect on inhibiting glucagon secretion (Nauck et al., 2002)
CPT: pharmacometrics & systems pharmacology Theoharides TC, et al
A manufacturer seeking to launch a generic ER must file a separate ANDA against the ER NDA and certify against the ER patent portfolio
Discuss persistent symptoms with your provider, as they may warrant bloodwork to rule out nutritional deficiencies or metabolic issues
Mediterranean diet and healtha narrative review